Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease.

Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is a research-based pharmaceutical company committed to create value for all stakeholders by accelerating the flow of innovative medicines that provide improved outcomes for individual patients and to help people live longer, healthier, more active lives.

Lilly is headquartered in Indianapolis, Indiana, U.S.A. and employs approximately 38,000 people worldwide. Approximately 7,900 Lilly employees are engaged in research and development. Clinical research is being conducted in more than 55 countries, with research and development facilities located in 6 countries and manufacturing plants located in 8 countries. Lilly products are marketed in 120 countries.

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes. Lilly’s Diabetes research and drug development is focused on potential new medicines to improve care of individual patients with diabetes and incorporates active biomarker research within most pipeline projects.

Within Hypo-RESOLVE, Lilly will share its knowledge in this field in various forms in order to facilitate improvement in our current understanding of clinical hypoglycaemia and its consequences for patients and for the broader community. As a partner in the project, Lilly will benefit from direct collaboration with various key groups and organisations to optimize future research work in the field.

Lilly has been actively engaged in several IMI 1 Diabetes Projects including SUMMIT, IMIDIA, DIRECT and StemBancc, and several other US-based public/private collaborations, including the AMP-Type 2 Diabetes consortium and the FNIH Biomarkers Consortium, as well as IMI 2 projects such as INNODIA, Beat DKD and LITMUS. Lilly participates to all work packages and co-leads Hypo-RESOLVE WP 6.

Dr Zvonko Milicevic, MD

is Associated Professor at JJ. Strossmayer University, Osijek, Croatia; clinical and research career in clinical diabetology; broad expertise in the field of diabetes management, autoimmune forms of diabetes, diabetic neuropathies, and drug development; more than 50 publications in scientific and clinical journals.

Dr Yongming Qu,

is Statistical Officer in Diabetes Clinical Research at Lilly with expertise in clinical trials and drug development, and rich research experience in statistical methodologies in the areas of innovative clinical trial design, incomplete data analysis, non-randomized studies, non-parametric methods, linear and nonlinear mixed models, and measurement error models; more than 50 publications in statistical and medical journals.

Kirsi Norrbacka, BSc (Pharmacy), MSc (Health Economics)

is an accomplished health outcomes scientist with expertise in Health Technology Assessment environments, economic modeling (cost-effectiveness analysis and budget impact models), systematic literature reviews, network meta-analysis, Real-World Evidence studies, health related quality of life, and Patient Reported Outcomes; 10 manuscripts; approx. 15 congress posters. Co-lead of WP 6 in HypoResolve.

Myriam Rosilio, MD, Msc

Medical Lead at Lilly diabetes in France- Adult and Pediatric Endocrinologist & Diabetologist. Participated the analysis of the pegylated lispro T1D trials. 23 peer reviewed publications in scientific and clinical journals.

Marco Orsini Federici

Medical Advisor at Lilly Diabetes in Italy – Endocrinologist and Diabetologist
Deep expertise in technologies applied to diabetes (CSII, CGM, artificial pancreas and EMRs). 10 publications referenced in pubmed.

Prof. Nanette Schloot

Medical Lead at Lilly Diabetes Germany, is also Associated Professor at Heinrich-Heine University Düsseldorf, Germany. Clinical and research career in clinical diabetology; broad expertise in the field of diabetes and endocrinology, autoimmune forms of diabetes, more than 130 publications in scientific and clinical journals.

Dr Christof M. Kazda, MD, MscPM

Medical Fellow in Exloratory R&D at LRL Indianapolis responsible for all early Phase Insulin- and Glucagon development programs. Internist, Diabetologist and Master in Pharmaceutical Medicine by training with decades of clinical trial experience. More than 50 publications in scientific and clinical journals.